Novavax Inc. shares surged after the company signed a $1.2 billion licensing agreement with Sanofi that includes commercializing a combined Covid-19 and flu shot. Novavax will receive $500 million in ...
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Shares in Novavax almost doubled after Sanofi struck a licensing deal worth up to $1.2bn to commercialise ...
LONDON — Novavax, the beleaguered maker of a Covid-19 vaccine, just got a boost of its own. The French pharma company Sanofi on Friday said it had reached a licensing deal to sell Novavax’s ...
Novavax on Friday erased doubts about its ability to remain in business and struck a licensing deal worth up to $1.2 billion with Sanofi for Covid-19 vaccines in exchange for a stake that doubles the ...
Novavax on Friday said it had struck a licensing deal worth at least $1.2 billion with Sanofi for its COVID-19 vaccine in ...
Novavax on Friday said it had struck a licensing deal worth at least $1.2 billion with Sanofi, opens new tab for its COVID-19 vaccine in exchange for a stake that valued the U.S. biotech firm at ...
French drugmaker gains access to Covid shot and other tech Sanofi also takes a small stake in Maryland-based company -rte-company state="{"_id":"0000018f-638a-d4b6 ...
Novavax shares (NVAX) surged after the vaccine maker said it had struck a licensing deal worth up to $1.4 billion with Sanofi (SNY, FR:SAN). Novavax shares were up 133% in recent trading at $10.11.
(Bloomberg) -- Novavax Inc. shares surged after the company signed a $1.2 billion licensing agreement with Sanofi that includes commercializing a combined Covid-19 and flu shot. Novavax will ...
The Gaithersburg biotech has lifted its going-concern warning after receiving a cash infusion. Novavax Inc. is getting a big cash infusion after signing a multibillion-dollar deal with French ...